Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
COVID-19, Vaccine Development, and Global Health Lessons from Ebola
Improving Cancer Outcomes with Early Diagnosis
Making A Social Contract That’s Enforceable
Treating Alzheimer’s Disease as an Autoimmune Condition
Fishing for New Drugs
Thoughts on the State of the Antimicrobial Arsenal
A MedTech Company That Thinks Like a Biopharma
Tapping the Potential of Psychedelics to Treat Psychiatric Conditions
Quantifying Neurodegeneration with Precision
Orasis Developing Eye Drops as Alternative to Reading Glasses
Reversing Disease Signals
Turning Cold Tumors Hot
Stabilizing Neuronal Connections to Treat Cognitive Impairment in Alzheimer’s
Our Annual Biotech Review/Preview with STAT’s Adam Feuerstein
An Effort to Eradicate Preventable Blindness
Seeking Success Where Others Have Failed
A New Antibiotic with a Unique Mechanism of Action Hits the Market
Improving Health with Better Data
An Effort to Bioprint a Transplantable Human Heart
How Doctors Are Cracking Difficult Cases with a Social Network
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths